INDIANAPOLIS, Aug. 17 /PRNewswire-AsiaNet/ — Decision does not affect other Lilly Alzheimer’s compounds in development Eli Lilly and Company (NYSE: LLY) will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer’s disease, because preliminary results from two ongoing long-term Phase III studies showed …
Read More »